COMP <GO>
URGN vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
UroGen Pharma Ltd. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: URGN 2
— JNJ 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $33.48 (-0.80%) • MKT CAP: $1.64B
roic
-35.00%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (URGN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | URGN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.70% | 67.90% | +20.80 | URGN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.94% | 2.97% | -12.91 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 21.40% | 6.00% | +15.40 | URGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 26.4 | 62.1 | -35.71 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.64B | $662.49B | -$660.86B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | URGN REV | JNJ REV | URGN GROSS % | JNJ GROSS % | URGN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $109.8M | $94.19B | 88.7% | 67.9% | -$162.7M | $19.70B |
| FY 2024 | $90.4M | $88.82B | 90.2% | 69.1% | -$97.1M | $19.84B |
| FY 2023 | $82.7M | $85.16B | — | — | -$76.4M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
URGN // BETA —
JNJ // BETA 1.08